New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 23, 2013
07:38 EDTARWRArrowHead begins phase 1 trial of ARC-520 for Hepatitis B infection treatment
Arrowhead Research announced that it has initiated dosing in a Phase 1 clinical trial of ARC-520, the company’s candidate for the treatment of chronic hepatitis B virus infection. Trial initiation followed successful completion of the Clinical Trial Notification regulatory process in Australia. The objectives of the study are to characterize the safety profile of ARC-520, determine maximum tolerated dose, and evaluate pharmacokinetics in healthy volunteers.The Phase 1 trial is a single-center, randomized, double-blind, placebo-controlled, single dose-escalation, first-in-human study of ARC-520 administered intravenously to healthy adult volunteers and is being conducted in Melbourne, Australia. Each dose cohort includes 6 subjects randomized at ratio of 1:2 to receive a single intravenous injection of either placebo or ARC-520. Arrowhead expects to complete this Phase 1 trial in Q4 and begin a Phase 2a trial in chronic HBV patients in 2014.
News For ARWR From The Last 14 Days
Check below for free stories on ARWR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 26, 2014
07:31 EDTARWRArrowhead Research volatility at low end of one-year range
Subscribe for More Information
August 22, 2014
10:06 EDTARWROptions with decreasing implied volatility
Options with decreasing implied volatility: AMPE FOLD GME YOKU SPLS DKS WUBA ARWR ACHN
August 20, 2014
11:42 EDTARWROptions with decreasing implied volatility
Subscribe for More Information
August 19, 2014
10:42 EDTARWROptions with decreasing implied volatility
Subscribe for More Information
August 18, 2014
10:57 EDTARWROptions with decreasing implied volatility
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use